Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
-
Corvus Pharma (CRVS) Announces Pricing of Public Offering of Common Stock
-
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Corvus Pharma (CRVS) to Offer Common Stock
-
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Corvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
-
Cantor Fitzgerald Reiterates Overweight Rating and $25 PT on Corvus Pharmaceuticals (CRVS) Following CPI-444 Data Results
-
Corvus Pharma (CRVS): Update From R&D Day - Cantor Fitzgerald
-
Corvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual Healthcare Conference on July 12
-
Corvus Pharmaceuticals (CRVS) IPO Opens Flat
-
Corvus Pharmaceuticals (CRVS) IPO Prices at $15, Low-End of Range
-
Corvus Announces Pricing of Initial Public Offering
-
Corvus Pharmaceuticals (CRVS) Files $115M IPO
